Understand the source comparison
Peptides Help with NASH Liver: Comparison of Mechanisms
Different peptide classes target distinct aspects of NASH pathophysiology. This table maps mechanism to clinical application and evidence strength. Thymosin peptides (alpha-1, beta-4) NF-κB inhibition, TGF-β1 modulation Reduces stellate cell activation and col
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different peptide classes target distinct aspects of NASH pathophysiology. This table maps mechanism to clinical application and evidence strength.
- Thymosin peptides (alpha-1, beta-4)
- NF-κB inhibition, TGF-β1 modulation
- Reduces stellate cell activation and collagen deposition
- 3/5. Phase 2 human data with modest effect sizes
- Adjunct to metabolic intervention for F2–F3 fibrosis
- Requires sustained administration; effects diminish without weight loss
- GLP-1 receptor agonists (semaglutide, tirzepatide)
- Appetite suppression, insulin sensitization, hepatic inflammation reduction
- Multi-pathway: reduces lipogenesis, improves insulin signaling, direct anti-inflammatory
- 4/5. Phase 3 RCT data showing NASH resolution
- First-line for NASH with obesity or T2DM
- Expensive; GI side effects; weight regain after discontinuation
- KPV anti-inflammatory peptides
- NF-κB translocation inhibition
- Selective inflammatory cascade suppression
- 2/5. Preclinical and early human safety data only
- Research protocols examining systemic inflammation
- Limited human NASH-specific data; oral bioavailability challenges
- Growth hormone secretagogues (ibutamoren, GHRP-2)
- IGF-1 elevation, improved insulin sensitivity
- Indirect: reduces hepatic steatosis through metabolic improvement
- 2/5. Metabolic studies show hepatic fat reduction but no fibrosis data
- Metabolic syndrome and insulin resistance protocols
- Does not directly address fibrosis; effects dependent on dietary compliance
- CCR2/CCR5 antagonist peptides
- Chemokine receptor blockade
- Prevents macrophage recruitment to hepatic tissue
- 3/5. Phase 2 data showing fibrosis improvement when combined with lifestyle
- Advanced fibrosis (F2–F3) as adjunct therapy
- Mechanism targets inflammation, not underlying metabolic driver